Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.

BMC Med Res Methodol · 2016 · PMC4751641 · PMID 26869168

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

borderline significantP =0.051so close (0.05 < p ≤ 0.1)

Also, borderline significant non-PH is present ( P =0.051, Grambsch-Therneau test).

also in 11,409 other papers

highly significantno p-value reported

3 ( d )) is 0.0044, seemingly highly significant and much smaller than the Cox test P -value.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.